Comparing two new treatments for axial spondyloarthritis
Treatments studied
Part of Bones, joints & muscles clinical trials.
This trial compares two newer medications for people with axial spondyloarthritis who have already tried a TNF inhibitor (a type of biologic) without success. The goal is to see which one works better at reducing symptoms like pain and stiffness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of axial spondyloarthritis or ankylosing spondylitis.
- Your disease is active, meaning you have significant pain, stiffness, or other symptoms.
- You have tried at least one TNF inhibitor (like etanercept, adalimumab, or infliximab) and it didn't work or you couldn't tolerate it.
- You have not taken an IL-17 inhibitor or a JAK inhibitor before.
- You do not have certain medical conditions like Crohn's disease, ulcerative colitis, cancer, stroke, heart attack, blood clots, cirrhosis, or severe kidney disease.
- If you could become pregnant, you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug for people with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine and pelvis). It also includes a group of healthy volunteers for comparison. The study aims to see if the drug is safe and effective.
This study looks at how well different newer medications work for people with axial spondyloarthritis or psoriatic arthritis. It focuses on those just starting treatment with bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
This study tests whether combining two types of immune-blocking drugs (an IL-17 inhibitor and a TNF inhibitor) works better than either alone for treating ankylosing spondylitis. It is for people whose symptoms are not well controlled with NSAIDs.
This study compares two types of biologic drugs (IL-17 inhibitors vs. anti-TNF drugs) in people with ankylosing spondylitis (a form of arthritis affecting the spine) who have already tried standard treatments. The goal is to see which drug works better for controlling symptoms.
This trial studies whether secukinumab (a targeted medicine given by injection) can reduce symptoms and disease activity in adults with active ankylosing spondylitis. You may be considered if other common anti-inflammatory medicines have not worked well enough or you could not take them.
This trial tests whether tofacitinib (a pill that reduces inflammation) can help people with early-stage axial spondyloarthritis, a type of arthritis that mainly affects the spine and pelvis. It's for those who have had symptoms for 2 years or less and have active disease with signs of inflammation in MRI or blood tests.
Hear when a new Axial Spondyloarthritis (AxSpA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.